Crescent Biopharma, Inc. (CBIO) Stock Grade

About Crescent Biopharma, Inc.'s fundamentals

Crescent Biopharma is a small-cap biotech company with a market capitalization of $123.5 million that reported flat revenue growth year-over-year at 0.0%, indicating no increase in sales during the period. The company posted a substantial net loss, resulting in a net margin of -1419.6%, meaning expenses significantly exceeded revenues. As a pre-profitability biotech firm, Crescent does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not applicable due to its unprofitable status.